Promoter Hypermethylation of the RB1 Gene in Glioblastomas

[1]  Y. Yonekawa,et al.  p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas , 2001, Brain pathology.

[2]  Y. Yonekawa,et al.  Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas , 2000, Journal of neuropathology and experimental neurology.

[3]  J. Harbour,et al.  Rb function in cell-cycle regulation and apoptosis , 2000, Nature Cell Biology.

[4]  W. Farrell,et al.  Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. , 2000, Cancer research.

[5]  K. Ichimura,et al.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.

[6]  W. Farrell,et al.  Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas. , 1999, Cancer research.

[7]  E. Estey,et al.  Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Y. Yonekawa,et al.  PTEN (MMAC1) Mutations Are Frequent in Primary Glioblastomas (de novo) but not in Secondary Glioblastomas , 1998, Journal of neuropathology and experimental neurology.

[9]  S. Groshen,et al.  Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. , 1998, Cancer research.

[10]  D. Louis,et al.  Molecular Genetic Correlates of p16, cdk4, and pRb Immunohistochemistry in Glioblastomas , 1998, Journal of neuropathology and experimental neurology.

[11]  Yasuhiro Yonekawa,et al.  Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas , 1997, Acta Neuropathologica.

[12]  S. Clark,et al.  Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. , 1997, Cancer research.

[13]  Y. Yonekawa,et al.  Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  W. Benedict,et al.  Altered retinoblastoma protein expression in nonsmall cell lung cancer , 1997, Cancer.

[15]  V P Collins,et al.  Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. , 1996, Oncogene.

[16]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Y. Yonekawa,et al.  Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas , 1996 .

[18]  S. Tsunoda,et al.  Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors. , 1996, International journal of oncology.

[19]  K. Cooney,et al.  Distinct regions of allelic loss on 13q in prostate cancer. , 1996, Cancer research.

[20]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[21]  B. Scheithauer,et al.  Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. , 1995, Cancer research.

[22]  D. Louis,et al.  The retinoblastoma gene is involved in malignant progression of astrocytomas , 1994, Annals of neurology.

[23]  A. Benabid,et al.  Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro‐endocrine lung carcinomas , 1994, International journal of cancer.

[24]  R. Hruban,et al.  Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. , 1994, Cancer research.

[25]  M Koslow,et al.  Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. , 1994, Journal of neurosurgery.

[26]  S. Hirohashi,et al.  Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. , 1994, Cancer research.

[27]  W. Benedict,et al.  Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. , 1994, Journal of the National Cancer Institute.

[28]  A. Thor,et al.  Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. , 1994, The New England journal of medicine.

[29]  W. Benedict,et al.  Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. , 1994, Cancer research.

[30]  W. Benedict,et al.  Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. , 1994, Cancer research.

[31]  A. Hogg,et al.  Molecular mechanisms of oncogenic mutations in tumors from patients with bilateral and unilateral retinoblastoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Sakai,et al.  CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. , 1993, Oncogene.

[33]  W. Benedict,et al.  Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression , 1993, International journal of cancer.

[34]  D. Louis,et al.  Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis , 1993, Brain pathology.

[35]  Å. Borg,et al.  The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression. , 1992, Cancer research.

[36]  P. Kleihues,et al.  Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K‐ras gene , 1992, Cancer.

[37]  T. Dryja,et al.  Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. , 1991, American journal of human genetics.

[38]  W. Lee,et al.  Human retinoblastoma susceptibility gene: cloning, identification, and sequence , 1987, Science.

[39]  W. Yung,et al.  PATHOLOGY AND GENETICS OF TUMOURS OF THE NERVOUS SYSTEM , 2002 .

[40]  N. Umesaki,et al.  The role of p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma , 2000, British Journal of Cancer.

[41]  Stefano Colella,et al.  Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas , 2000, Laboratory Investigation.

[42]  K. Ichimura,et al.  Deregulation of the p 14 ARF / MDM 2 / p 53 Pathway Is a Prerequisite for Human Astrocytic Gliomas with G 1S Transition Control Gene Abnormalities 1 , 2000 .

[43]  P. Kleihues,et al.  Primary and secondary glioblastomas: from concept to clinical diagnosis. , 1999, Neuro-oncology.

[44]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.